Advertisement

Systemic Chemotherapy for Metastatic Hormone-Sensitive Prostate Cancer

  • Kyong Tae Moon
  • Tag Keun Yoo
Chapter

Abstract

Traditionally, long-term androgen deprivation therapy (ADT) has been considered as the standard of care (SOC) for men with metastatic hormone-sensitive prostate cancer. But, unfortunately several months after the ADT, tumors become castration-resistant, and eventually all patients suffer from disease progression. In 2004, two randomized phase 3 trials demonstrated for the first time a survival benefit in patients with metastatic castration-resistant prostate cancer (mCRPC) utilizing docetaxel-based chemotherapy, setting a new standard of care for patients with mCRPC [1, 2]. The benefit of docetaxel-based chemotherapy in patients with mCRPC suggested that early chemotherapy might improve the prognosis of patients with metastatic hormone-sensitive prostate cancer (mHSPC). In bringing docetaxel into the hormone-sensitive setting, the rationale was to preemptively eradicate cancer cells inherently insensitive to ADT by acting on cellular targets outside of the androgen-signaling pathway, thus improving clinical outcomes. Recently, final results of three large, randomized, phase 3 trials (GETUG-AFU 15, CHAARTED, and STAMPEDE) evaluating the value of up-front docetaxel chemotherapy in mHSPC were reported.

References

  1. 1.
    Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med. 2004;351(15):1502–12.CrossRefPubMedGoogle Scholar
  2. 2.
    Petrylak DP, Tangen CM, Hussain MH, Lara PN Jr, Jones JA, Taplin ME, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med. 2004;351(15):1513–20.CrossRefPubMedGoogle Scholar
  3. 3.
    Gravis G, Fizazi K, Joly F, Oudard S, Priou F, Esterni B, et al. Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial. Lancet Oncol. 2013;14(2):149–58.CrossRefPubMedGoogle Scholar
  4. 4.
    Gravis G, Boher JM, Joly F, Soulie M, Albiges L, Priou F, et al. Androgen deprivation therapy (ADT) plus docetaxel versus ADT alone in metastatic non castrate prostate cancer: impact of metastatic burden and long-term survival analysis of the randomized phase 3 GETUG-AFU15 trial. Eur Urol. 2016;70(2):256–62.CrossRefPubMedGoogle Scholar
  5. 5.
    Sweeney CJ, Chen YH, Carducci M, Liu G, Jarrard DF, Eisenberger M, et al. Chemohormonal therapy in metastatic hormone-sensitive prostate cancer. N Engl J Med. 2015;373(8):737–46.CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Liaw BC, Oh WK. Is docetaxel chemotherapy a new standard of care for metastatic hormone-sensitive prostate cancer? Am J Hematol/Oncol. 2015;11(9)Google Scholar
  7. 7.
    James ND, Sydes MR, Clarke NW, Mason MD, Dearnaley DP, Spears MR, et al. Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial. Lancet. 2016;387(10024):1163–77.CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Tsao CK, Galsky MD, Oh WK. Docetaxel for metastatic hormone-sensitive prostate cancer: urgent need to minimize the risk of neutropenic fever. Eur Urol. 2016;70(5):707–8.CrossRefPubMedGoogle Scholar
  9. 9.
    Smith TJ, Bohlke K, Lyman GH, Carson KR, Crawford J, Cross SJ, et al. Recommendations for the use of WBC growth factors: American Society of clinical oncology clinical practice guideline update. J Clin Oncol Off J Am Soc Clin Oncol. 2015;33(28):3199–212.CrossRefGoogle Scholar
  10. 10.
    Katzenwadel A, Wolf P. Androgen deprivation of prostate cancer: leading to a therapeutic dead end. Cancer Lett. 2015;367(1):12–7.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Nature Singapore Pte Ltd. 2018

Authors and Affiliations

  1. 1.Department of UrologyNowon Eulji Medical Center, Eulji UniversitySeoulKorea

Personalised recommendations